Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic

Core Insights - Absci Corporation has launched an endometriosis advisory board for its ABS-201 program, aimed at developing a new therapeutic antibody treatment for endometriosis [1][4] - The advisory board consists of experts from prestigious institutions, emphasizing the company's commitment to clinical rigor and innovative treatment options [5][6] Group 1: Endometriosis Overview - Endometriosis is a chronic inflammatory disease affecting approximately 190 million people globally, characterized by endometrium-like lesions outside the uterus [2] - Current treatments primarily involve hormonal therapies and pain medications, which do not address the underlying pathology of the disease, highlighting a significant unmet medical need [2] Group 2: ABS-201 Treatment Details - ABS-201 is an anti-prolactin receptor antibody that targets a non-hormonal pathway in endometriosis, potentially treating the condition without affecting ovulation or fertility [3] - The treatment is designed for subcutaneous self-administration with an extended half-life, allowing for infrequent dosing and improved patient convenience [3] Group 3: Advisory Board Contributions - The advisory board will assist in study design, clinical strategy, and patient-informed endpoints as Absci progresses ABS-201 towards Phase 2 studies, expected to begin in Q4 2026 [4][9] - Experts on the board include Dr. Hugh Taylor from Yale University and Dr. Linda Giudice from UCSF, who emphasize the need for diverse treatment options for endometriosis patients [5][7][8] Group 4: Company Background - Absci is focused on advancing drug discovery through generative design, aiming to create innovative biologics more efficiently [10] - The company is headquartered in Vancouver, WA, with additional facilities in New York City and Switzerland, and is developing a pipeline of AI-designed therapeutics, including ABS-201 for endometriosis [10]